1 Sanqiang Road, Xinzhen, Fangshan District, Beijing, China
Zip code:102413  
Tel:+86-10-6935 8839


China Isotope & Radiation Corporation Listed on HKEx

China Isotope & Radiation Corporation Listed on HKEx

Page view
China Isotope & Radiation Corporation (CIRC), the leading enterprise of nuclear technology application industry in China, has been successfully listed on Hong Kong Exchanges and Clearing Limited (HKEx) at 09:30 on 6th July, 2018. It is the fifth listed enterprise under China National Nuclear Corporation (CNNC).


China Isotope & Radiation Corporation (CIRC), the leading enterprise of nuclear technology application industry in China, has been successfully listed on Hong Kong Exchanges and Clearing Limited (HKEx) at 09:30 on 6th July, 2018. It is the fifth listed enterprise under China National Nuclear Corporation (CNNC), which makes a new breakthrough in the international capital market by CNNC and CIRC, and opens a new chapter in the development of China's nuclear technology application industry. It is of great significance to promote the progress of nuclear technology application industry, and to maintain and increase the value of state-owned assets.


During the event, Yu Jianfeng, deputy secretary of CPC Leading Group and general manager of CNNC, and Meng Yanbin, Communist Party secretary and chairman of CIRC, jointly stroke a gong and started trading for CIRC. Cao Shudong, a member of the Party group and deputy general manager of CNNC, as well as representatives from HKEx, sponsors, shareholders, investment banks, intermediaries and media reporters at home and abroad, witnessed this historic moment.



It is understood that CIRC is a specialized company of CNNC’s nuclear technology application industry, aiming at building an important well-known enterprise in the field of nuclear technology application globally. Before the listing, CNNC has held 98.45% shares of CIRC directly or indirectly.


The issue price of CIRC is HK$ 21.6 per share. A total of 79,968,700 shares are issued, 70% of which are for international sale, 30% are for public sale, and 15% are for over-allotment. The first raise fund was expected to invest in two radiopharmaceuticals production and R&D bases for imaging diagnosis and treatment in Hebei Province and Sichuan Province by CIRC, in order to enhance production and R&D capabilities.